TITLE:
Immunotherapy of Malignant Tumors Using Antisense Anti-IGF-I Approach: Case of Glioblastoma
AUTHORS:
Annabelle Trojan, Lina M. Jay, Heliodor Kasprzak, Donald D. Anthony, Jerzy Trojan
KEYWORDS:
Immunogene Therapy, Malignant Tumors, Glioblastoma, IGF-I, Antisense
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.5 No.7,
June
19,
2014
ABSTRACT:
The review article
describes the criteria established for methodology of antisense anti IGF-I
therapy of malignant tumors, particularly of glioblastoma. The cancer patients,
after classical therapy of
surgery, radiotherapy and chemotherapy, have undergone the injection of
genetically modified autologous malignant cells—transfected by IGF-I
antisense/triple helix expression vectors. For all cancer patients supervised for up
to 19 months, the period corresponding to minimum survival of glioblastoma
patients, the following common immune criteria for “anti IGF-I” strategy were
admitted: 1) characteristics of cell “vaccines”—absence of IGF-I and expression
of MHC-I in cloned transfected cells; 2) the peripheral blood lymphocytes, PBL
cells, removed after every of two successive vaccinations, demonstrate an
increasing level of CD8+ and
CD8+28+ molecules
(with a switch from CD8+11b+ to CD8+11b-).